Table 2. Laboratory parameters related to cardiac, hepatic and renal function on the admission of patients diagnosed with COVID-19, according to the severity of the disease.
Each value of the table represents the mean, median –: not available; M: Male, F: Female; S: statistically significant difference between mild and severe cases N; S: non–significant difference between mild and severe cases (+): proteinuria or hematuria +, ++ o +++; **: upper BUN limit according to age <60, 60–80 and >80 years; for men it is 8.0, 9.5 and 8.3 mmol/L respectively, and for women 7.5, 8.8 and 8.3 mmol/L respectively. Other classifications: R: Recovered; D: Dead; NScr: Normal base serum creatinine; EScr: Elevated base serum creatinine; NLF: Normal liver function; ALF: Abnormal liver function; LI: Liver injury
| Parameter | N° of ses | Reference range | Severity of the disease | P value | Reference | |||
|---|---|---|---|---|---|---|---|---|
| Total cases | Mild cases | Serious cases | Other classifications | |||||
| Troponin I (pg/mL) | 138 | <26.2 | 6.4 | 5.1 | 11 | S | [23] | |
| 150 | 2–28 | – | R: 3.5; D: 30.3 | S | [30] | |||
| 41 | ≤28 | 3.4 | 3.5 | 3.3 | – | [25] | ||
| Troponin I (µg/mL) | 12 | 0–0.1 | 0.95 | – | – | – | [26] | |
| Creatine kinase-MB (U/L) | 138 | <25 | 14 | 13 | 18 | S | [23] | |
| Creatine kinase-MB (ng/mL) | 12 | 0–2.37 | 2.0 | – | – | – | [26] | |
| Myoglobin (ng/mL) | 99 | 0–146.9 | 67.9 | – | – | – | [24] | |
| 12 | 0–110 | 43.9 | – | – | – | [26] | ||
| 65 | 0–106 | 58.6 | 21.6 | 63.4 | – | [28] | ||
| 150 | 0–146.9 | – | R: 77.7; D: 258.9 | S | [30] | |||
| Natriuretic peptide (pmol/L) | 4 | 0–23.1 | 43.9 | – | – | – | [26] | |
| Alanin aminotransferase (U/L) | 138 | 9–50 | 24 | 23 | 35 | S | [23] | |
| 99 | 9–50 | 39 | – | – | – | [24] | ||
| 41 | – | 32 | 27 | 49 | S | [25] | ||
| 40 | – | 22.5 | 19 | 27 | – | [22] | ||
| 12 | 0–45 | 31.6 | – | – | – | [26] | ||
| 105 | M: 9–50 F: 7– 40 | 23.5 | 22 | 27.8 | S | [49] | ||
| 18 | 9–50 | 36.4 | – | – | – | [27] | ||
| 193 | M: 0– 41 F: 0–33 | 20 | 19 | 21 | – | [28] | ||
| 150 | 9–50 | – | R: 48.7; D: 170.8 | – | [30] | |||
| 701 | – | 35 | NScr: 36; EScr: 32 | – | [29] | |||
| 417 | ≤40 | 21 | NLF: 17; ALF: 27; LI: 47 | S | [50] | |||
| Aspartataminotransferase (U/L) | 138 | 15–40 | 31 | 29 | 52 | S | [23] | |
| 99 | 15–40 | 34 | – | – | – | [24] | ||
| 41 | ≤40 | 34 | 34 | 44 | NS | [25] | ||
| 12 | 0–45 | 40 | – | – | – | [26] | ||
| 50 | M: 15–40 F: 13–35 | 24.2 | 22 | 46.3 | S | [49] | ||
| 18 | 15–40 | 34.9 | – | – | – | [27] | ||
| 193 | M: 0–40 F: 0–32 | 30 | 26 | 40 | – | [28] | ||
| 40 | – | 34.1 | 25.9 | 51.2 | – | [22] | ||
| 150 | 15–40 | – | R: 48.7; D: 288.9 | NS | [30] | |||
| 701 | – | 42 | NScr: 41; EScr: 47 | NS | [29] | |||
| 417 | ≤40 | 26.5 | NLF: 23; ALF: 34; LI: 47 | S | [50] | |||
| Gamma-glutamyltranspeptidase(U/L) | 14 | 7–45 | 42.2 | – | – | – | [27] | |
| 417 | ≤49 | 34.1 | NLF: 21; ALF: 36; LI: 135 | S | [50] | |||
| Total bilirubin (mmol/L) | 138 | 5–21 | 9.8 | 9.3 | 11.5 | S | [23] | |
| 701 | – | 12 | NScr: 11; EScr: 21 | NS | [29] | |||
| 41 | – | 11.7 | 10.7 | 14 | S | [25] | ||
| Total bilirubin (µmol/L) | 50 | 0–18.8 | 10.2 | 10 | 10.6 | NS | [49] | |
| 12 | 3–22 | 8.2 | – | – | – | [26] | ||
| 40 | – | 10.3 | 8.8 | 13.2 | – | [22] | ||
| 193 | M: 0–26 F: 0–21 | 8.82 | 7.85 | 13.39 | – | [28] | ||
| 99 | 0–21 | 15 | – | – | – | [24] | ||
| 150 | 0–26 | – | R: 5.1; D: 8.6 | S | [30] | |||
| 417 | ≤17.1 | 10.9 | NLF: 9; ALF: 17; LI: 17 | S | [50] | |||
| Alkaline phosphatase (U/L) | 417 | ≤135 | 61 | NLF: 59; ALF: 63; IL: 68 | S | [50] | ||
| Albumin (g/L) | 99 | 40–55 | 31.6 | – | – | – | [24] | |
| 41 | – | 31.4 | 34.7 | 27.9 | S | [25] | ||
| 12 | 40–55 | 37.7 | – | – | – | [26] | ||
| 49 | 40–55 | 41.6 | 42 | 37.2 | S | [49] | ||
| 193 | 35–52 | 34.2 | 35.2 | 32.6 | – | [28] | ||
| 150 | 35–52 | – | R: 33; D: 28.8 | S | [30] | |||
| Blood ureanitrogen (mmol/L) | 138 | 2.8–7.6 | 4.4 | 4.0 | 5.9 | S | [23] | |
| 99 | 3.6–9.5 | 5.9 | – | – | – | [24] | ||
| 12 | 3.2–7.1 | 5.4 | – | – | – | [26] | ||
| 87 | 2.9–8.2 | 3.8 | 3.72 | 4.14 | NS | [51] | ||
| 193 | 3.1–8 | 4.4 | 3.9 | 6.43 | – | [28] | ||
| 40 | – | 3.2 | 3.2 | 3.3 | – | [22] | ||
| 701 | ** | 5.7 | NScr: 4.8; EScr: 11 | S | [29] | |||
| 150 | 3.1–8 | – | R: 5.1; D: 8.65 | S | [30] | |||
| Serum creatinine (µmol/L) | 138 | 64–104 | 72 | 71 | 80 | S | [23] | |
| 99 | 57–111 | 75.6 | – | – | – | [24] | ||
| 41 | ≤133 | 74 | 73 | 79 | NS | [25] | ||
| 12 | 58–110 | 85.6 | – | – | – | [26] | ||
| 40 | – | 67.3 | 64.0 | 74.2 | – | [22] | ||
| 87 | M: 54–133 F: 44–106 | 65.2 | 65.3 | 71 | NS | [51] | ||
| 193 | M: 59–104 F:45–84 | 66 | 63 | 73 | – | [28] | ||
| 701 | M: 104 F: 84 | 77 | NScr: 68; EScr: 132 | S | [29] | |||
| 150 | 59–104 | – | R: 72.1; D: 91.2 | S | [30] | |||
| Proteinuria (+) | 83 | Negative | 35% | 28% | 58% | [51] | ||
| 129 | Negative | 59% | 55% | 66% | [28] | |||
| 442 | Negative | 44% | NScr: 40%; EScr: 70% | [29] | ||||
| Hematuria (+) | 83 | Negative | 29% | 22% | 53% | [51] | ||
| 129 | Negative | 44% | 44% | 45% | [28] | |||
| 442 | Negative | 27% | NScr: 23%; EScr: 53% | [29] | ||||